Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2023-10-04 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Block admission six monthly return
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated '04 October 2023'. It announces a 'Block admission six monthly return' related to employee share option schemes, detailing the number of securities over a specific period (2 April 2023 to 1 October 2023). The presence of the RNS header, the specific nature of the announcement (a routine regulatory return regarding share block admission), and the concluding statement referencing RNS as the news service of the London Stock Exchange strongly indicate this is a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate general category for a routine regulatory filing disseminated via RNS is 'Regulatory Filings' (RNS). It is not short enough to definitively trigger the RPA rule, and it contains specific data that fits better than the general fallback.
2023-10-04 English
Final Results
Earnings Release Classification · 99% confidence The document explicitly states it announces the "Final results for the year ended 31 March 2023." It provides key financial highlights (revenues, loss for the year, cash position) and operational updates. This structure is characteristic of an Earnings Release (ER) or a summary preceding a full Annual Report (10-K) or Interim Report (IR). Since it covers the full fiscal year and includes a Chairman's Statement and detailed business performance review, it is more comprehensive than a typical ER, but it is presented as an RNS announcement summarizing the results. Crucially, it mentions that the 'Annual Report and Accounts for the year ended 31 March 2023' and the 'Notice of the Company's Annual General Meeting ("AGM") are being posted to shareholders shortly. This indicates the current document is the preliminary announcement of the results, not the full 10-K document itself. Therefore, the most appropriate classification is Earnings Release (ER). FY 2023
2023-09-29 English
Update on AI/ML-Ab service offering
Regulatory Filings Classification · 98% confidence The document is clearly identified as an RNS announcement by the header "RNS Number : 5440K" and the concluding paragraph stating, "This information is provided by RNS, the news service of the London Stock Exchange." The content is a brief update on receiving a purchase order for a new service offering ("AI/ML-AbTM service offering"). This type of immediate, non-periodic corporate news release that doesn't fit a more specific category (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or announcement. Since 'RNS' is explicitly mentioned as the source and it's a general announcement, the code RNS is the most appropriate fit, as it serves as the general regulatory announcement fallback.
2023-08-29 English
Appointment of interim CFO
Board/Management Information Classification · 98% confidence The document is identified by the header 'RNS Number : 2702K' and contains an announcement titled 'Appointment of interim CFO'. This is a specific corporate event disclosure regarding a change in senior management. This directly matches the definition for Board/Management Information (MANG). Although it is distributed via RNS, the content is specific enough to warrant the MANG classification over the general RNS fallback.
2023-08-24 English
Update on AI/ML-Ab™ antibody discovery service
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated '21 August 2023'. It contains an announcement from 'Fusion Antibodies plc' regarding an 'Update on AI/ML-AbTM antibody discovery service' and the signing of a commercial agreement. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory news service announcement, which fits the definition of 'Regulatory Filings' (RNS) as a broad category for official, non-specific regulatory disclosures, especially those originating from the LSE's RNS system.
2023-08-21 English
Update on restructure and cost savings
Earnings Release Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date stamp typical of regulatory news services (RNS). The content is an 'Update on restructure and cost savings' which discusses operational changes, cost reductions, and mentions future announcements contingent on the 'publication of the Company's annual report and accounts for the year ended 31 March 2023'. This is a specific operational/corporate update released via the RNS system, rather than a full financial report (10-K or IR) or a specific announcement like a dividend (DIV) or director dealing (DIRS). Since it is a general corporate announcement disseminated through the London Stock Exchange's news service (RNS), and it doesn't fit neatly into the other specific categories (like ER, CT, or CAP), the most appropriate classification is the general regulatory filing category. FY 2023
2023-08-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.